La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Nabriva Therapeutics Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

H. Hogan

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.2yrs
Proprietà del CEO	n/a
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	6.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Nabriva Therapeutics to effect 1-for-25 reverse stock split

Sep 15

Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug Xenleta

Jul 18

Need To Know: The Consensus Just Cut Its Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates For 2022

Apr 04

Bullish: Analysts Just Made A Noticeable Upgrade To Their Nabriva Therapeutics plc (NASDAQ:NBRV) Forecasts

Aug 11

We Think Some Shareholders May Hesitate To Increase Nabriva Therapeutics plc's (NASDAQ:NBRV) CEO Compensation

Jul 22

AMMINISTRATORE DELEGATO

H. Hogan (61 yo)

1.2yrs

Mandato

Mr. H. Michael Hogan III is Chief Executive Officer of Nabriva Therapeutics plc from July 6, 2023. He serves as Director of Metacrine, Inc. since March 23, 2023. He is Director of Otonomy, Inc. from Februa...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Colin Broom	Director	7yrs	US$40.00k	0.042% $ 0.1
H. Hogan	Chief Executive Officer	1.2yrs	Nessun dato	Nessun dato
David Maggio	Chief Financial Officer	1.3yrs	Nessun dato	Nessun dato

1.3yrs

Durata media

64yo

Età media

Gestione esperta: Il team dirigenziale di NBRV.F non è considerato esperto (durata media 1.2 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Colin Broom	Director	7.3yrs	US$40.00k	0.042% $ 0.1
Daniel Burgess	Independent Chairman of the Board	7.3yrs	US$90.00k	0.013% $ 0.04
Mark H. Corrigan	Independent Director	3.3yrs	US$50.00k	0.0089% $ 0.03
Stephen Webster	Independent Director	7.3yrs	US$65.00k	0.014% $ 0.05
Steven Gelone	Director	3.5yrs	US$579.23k	0.041% $ 0.1
Charles Rowland	Independent Director	7.3yrs	US$55.00k	0.019% $ 0.06
Theodore Schroeder	Director	6.1yrs	US$753.56k	0.26% $ 0.8
Lisa Dalton	Independent Director	3.3yrs	US$47.50k	0.011% $ 0.04

6.7yrs

Durata media

64.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NBRV.F sono considerati esperti (durata media dell'incarico 6.6 anni).

Nabriva Therapeutics Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer

Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer

Nabriva Therapeutics plc, Annual General Meeting, Aug 11, 2022

CEO & Director recently bought US$57k worth of stock

CEO & Director recently bought US$57k worth of stock

Less than half of directors are independent

Recent updates

Nabriva Therapeutics plc Files Form 15

Nasdaq to Delist the Ordinary Shares of Nabriva Therapeutics

Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index

Nabriva Therapeutics Receives A Delisting Determination Letter from Nasdaq

Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer

Nabriva Therapeutics plc announced delayed 10-Q filing

Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer

Nabriva Therapeutics plc Announces Positive Topline Results from Phase 1 Trial of XENLETA (lefamulin) in Adult Patients with Cystic Fibrosis

Nabriva Therapeutics plc to Report Q3, 2022 Results on Nov 10, 2022

Nabriva Therapeutics to effect 1-for-25 reverse stock split

Nabriva Therapeutics plc Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic Fibrosis

Nabriva Therapeutics plc to Report Q2, 2022 Results on Aug 03, 2022

Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug Xenleta

Nabriva Therapeutics plc, Annual General Meeting, Aug 11, 2022

The Nasdaq Stock Market LLC Approves Nabriva Therapeutics' Transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market

Consensus revenue estimates fall by 10%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Nabriva Therapeutics plc to Report Q1, 2022 Results on May 05, 2022

No longer forecast to breakeven

Nabriva Therapeutics plc Announces First Patient Enrolled in Phase 1 Trial of Xenleta® (Lefamulin) in Adult Patients with Cystic Fibrosis

Consensus revenue estimates fall by 17%

Need To Know: The Consensus Just Cut Its Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates For 2022

No longer forecast to breakeven

Forecast to breakeven in 2024

CEO & Director recently bought US$57k worth of stock

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.90 loss in 3Q 2020)

CEO & Director recently bought US$57k worth of stock

Consensus revenue estimates increase to US$29.6m

Bullish: Analysts Just Made A Noticeable Upgrade To Their Nabriva Therapeutics plc (NASDAQ:NBRV) Forecasts

Second quarter 2021 earnings released: US$0.29 loss per share (vs US$1.37 loss in 2Q 2020)

Independent Director George Talbot has left the company

Less than half of directors are independent

We Think Some Shareholders May Hesitate To Increase Nabriva Therapeutics plc's (NASDAQ:NBRV) CEO Compensation

No longer forecast to breakeven

Consensus forecasts updated

Sinovant Sciences and Nabriva Therapeutics plc Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)

Consensus forecasts updated

First quarter 2021 earnings released: US$0.53 loss per share (vs US$2.46 loss in 1Q 2020)

Nabriva Therapeutics plc 2021 Q1 - Results - Earnings Call Presentation

Nabriva Therapeutics plc has completed a Follow-on Equity Offering in the amount of $33.7 million.

Consensus revenue estimates increase to US$30.8m

Consensus forecasts updated

Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin)

Chief Financial Officer has left the company

Nabriva Therapeutics Appoints Steven Gelone to Its Board of Directors

Full year 2020 earnings released: US$5.41 loss per share (vs US$11.15 loss in FY 2019)

Revenue and earnings beat expectations

Nabriva Therapeutics plc to Report Q4, 2020 Results on Mar 11, 2021

New 90-day low: US$1.92

Nabriva Therapeutics plc Announces A Hearing on May 14, 2021

Nabriva Therapeutics plc Announces the Publication of A Study Documenting the High Rates of Macrolide-Resistant Streptococcus Pneumoniae Throughout the United States

When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Breakeven?

Nabriva Therapeutics Announces Retirement of Gary Sender as Chief Financial Officer, Effective as of March 12, 2021

Nabriva Therapeutics announces proposed public offering

New 90-day low: US$3.40

Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China

Nabriva Therapeutics shares gain as Sinovant expands Xenleta support in China

Nabriva Therapeutics plc 2020 Q3 - Results - Earnings Call Presentation

Third quarter 2020 earnings released: US$0.09 loss per share

Revenue and earnings beat expectations

Nabriva Therapeutics plc to Report Q3, 2020 Results on Nov 05, 2020

Analysts update estimates

New 90-day low: US$0.51

Nabriva Therapeutics plc Announces XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)

New 90-day low: US$0.53

New 90-day low - US$0.59

Earnings released

Nabriva Therapeutics plc to Report Q2, 2020 Results on Aug 06, 2020

AMMINISTRATORE DELEGATO